Publication:
Allogeneic hematopoietic stem cell transplantation for children with severe aplastic anemia

0
0

Issued Date

2013

Resource Type

Article

File Type

application/pdf

ISSN

1252208

Other identifier(s)

2-s2.0-84876862072

Rights Holder(s)

มหาวิทยาลัยศรีนครินทรวิโรฒ

Bibliographic Citation

Journal of the Medical Association of Thailand. Vol 96, No.SUPPL.1 (2013), p.S18-S24

Suggested Citation

Hutspardol S., Sirachainan N., Anurathapan U., Pakakasama S., Songdej D., Chuansumrit A., Sirireung S., Panthangkool W., Hongeng S. Allogeneic hematopoietic stem cell transplantation for children with severe aplastic anemia. Journal of the Medical Association of Thailand. Vol 96, No.SUPPL.1 (2013), p.S18-S24. Retrieved from: https://hdl.handle.net/20.500.14740/6784

Title

Allogeneic hematopoietic stem cell transplantation for children with severe aplastic anemia

Author(s)

Hutspardol S.
 Sirachainan N.
 Anurathapan U.
 Pakakasama S.
 Songdej D.
 Chuansumrit A.
 Sirireung S.
 Panthangkool W.
 Hongeng S.

Abstract

Objective: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative treatment for severe aplastic anemia (SAA). This is a single institutional review to study the feasibility of using allo-SCT for Thai children with SAA. Material and Method: Nine children with SAA (7 matched-sibling donor-SCT, 1 matched-unrelated donor-SCT and 1 haploidentical- SCT) underwent allo-SCT between October 2002 and September 2010. Cyclophosphamide and anti-thymocyte globulin (CY/ATG) were used as conditioning regimen for 4 patients with matched-sibling donor-SCT. CY/ATG and fludarabine were used for 3 patients with matched-sibling donor-SCT and one patient with haplo-identical SCT. One matched-unrelated donor-SCT received CY/ATG and total body irradiation. Results: Eight of 9 patients (89%) achieved neutrophil engraftment within 13.5 days (range 6.0-22.0). One matched-sibling donor-SCT recipient who failed to achieve engraftment died from acute renal failure and gram-negative sepsis on day 21 post allo-SCT. One matched-sibling donor-SCT case developed late graft failure on day 72 and died from invasive fungal infection. For graft versus host disease (GVHD), a haplo-identical-SCT patient died from steroid refractory grade IV acute GVHD. At last follow-up, six patients (67%) alive at a median follow-up time of 76.4 months (range 2.3-88.8). Overall survival (OS) and event-free survival (EFS) at 5 year was 63% and 65%, respectively. Conclusion: Allo-SCT is a feasible curative treatment for children with SAA in Thailand. Graft failure and severe GVHD in alternative donors SCT are responsible for major causes of death. OS and EFS probabilities are stable after the first year post transplant.

Subject(s)

Aciclovir
 Amphotericin B
 Ciprofloxacin
 Corticosteroid
 Cyclophosphamide
 Cyclosporin A
 Fludarabine
 Granulocyte colony stimulating factor
 Itraconazole
 Mesna
 Metenolone enantate
 Methotrexate
 Mycophenolic acid 2 morpholinoethyl ester
 Penicillin derivative
 Tacrolimus
 Thymocyte antibody
 Allogeneic hematopoietic stem cell transplantation
 Aplastic anemia
 Article
 Blood transfusion
 Bone marrow transplantation
 Candidiasis
 Child
 Chimera
 Clinical article
 Continuous infusion
 Donor
 Engraftment
 Event free survival
 Female
 Fluorescence in situ hybridization
 Follow up
 Graft rejection
 Graft versus host reaction
 Human
 Male
 Neutrophil count
 Overall survival
 Peripheral blood stem cell
 Remission
 School child
 Thrombocyte count
 Thrombocyte transfusion
 Adolescent
 Anemia, Aplastic
 Child
 Child, Preschool
 Feasibility Studies
 Female
 Graft vs Host Disease
 Host vs Graft Reaction
 Humans
 Immunosuppressive Agents
 Infant
 Male
 Risk Factors
 Stem Cell Transplantation
 Survival Analysis
 Transplantation, Homologous

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/6784

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By